10/13/2011

Banner Pharmacaps said the FDA accepted for review the firm's 75-milligram bexarotene softgel capsule. The drug, a generic version of Eisai's Targretin, is indicated for cutaneous T-cell lymphoma. Banner can claim 180-day market exclusivity if its product is approved.

Related Summaries